glp-1 and bipolar meds bipolar: any differences noticed? The GLP-1 receptor agonist liraglutide

(2012, Diabetes ) demonstrated SCFA-stimulated GLP-1 secretion via FFAR2/3 signaling

People with a history of medullary thyroid cancer, gallbladder disease or pancreatitis, as well as those with multiple endocrine neoplasia syndrome type 2 should avoid taking these drugs

But the evidence does not show the same mechanism, magnitude, durability, or clinical-outcome data expected from GLP-1-based obesity medications

Although limited data exists on pregnancy exposures, animal studies showed fetal effects at high doses

This is intended for those who need additional amounts of Vitamins A, D, E and K

And leading that charge